Patent classifications
A23V2250/612
COMPOSITION FOR INHIBITING IMMUNE CELL PROLIFERATION COMPRISING SIALYLLACTOSE OR DERIVATIVE THEREOF AND METHOD THEREOF
Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG.sub.2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.
COMPOSITION FOR INHIBITING IMMUNE CELL PROLIFERATION COMPRISING SIALYLLACTOSE OR DERIVATIVE THEREOF AND METHOD THEREOF
Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG.sub.2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.
COLD EXTRACTION METHOD FOR CANNABINOIDS AND TERPENES FROM CANNABIS BY POLYUNSATURATED LIPID-BASED SOLVENTS
The invention relates to methods for producing botanical extracts comprising cannabinoids and terpenes using cold extraction with highly polyunsaturated lipid solvents. These methods allow for the extraction of cannabinoids and terpenes while leaving behind impurities that are commonly found in organic solvent extraction methods.
COLD EXTRACTION METHOD FOR CANNABINOIDS AND TERPENES FROM CANNABIS BY POLYUNSATURATED LIPID-BASED SOLVENTS
The invention relates to methods for producing botanical extracts comprising cannabinoids and terpenes using cold extraction with highly polyunsaturated lipid solvents. These methods allow for the extraction of cannabinoids and terpenes while leaving behind impurities that are commonly found in organic solvent extraction methods.
COMPOSITIONS OF LIPASES AND PREGASTRIC ESTERASES FOR MAMMALIA NUTRITION SUPPORT
Compositions and methods are disclosed containing lingual lipase or another pregastric esterase as a nutritional composition for use in neonatal mammals or mammals with fat maldigestion. The compositions may be used as a stand-alone feed, or an additive to milk, milk or replacers. The composition may also include micronutrients, macronutrients, and bioactive dietary components for neonate mammals or mammals of any age with fat maldigestion Mammals include ruminants, porcines, horses, camelids, dogs, cats, or humans. Lingual lipase or pregastric esterase as a nutritional supplement may substantially improve the digestion of fats in mammals unable to effectively digest fats. The lingual lipase or esterase is preferably from an animal source. The composition may contain butterfat, micellar casein, whey, non-denatured proteins, and a source of lactose. Methods of treating fat maldigestion with the compositions are also disclosed.
COMPOSITIONS OF LIPASES AND PREGASTRIC ESTERASES FOR MAMMALIA NUTRITION SUPPORT
Compositions and methods are disclosed containing lingual lipase or another pregastric esterase as a nutritional composition for use in neonatal mammals or mammals with fat maldigestion. The compositions may be used as a stand-alone feed, or an additive to milk, milk or replacers. The composition may also include micronutrients, macronutrients, and bioactive dietary components for neonate mammals or mammals of any age with fat maldigestion Mammals include ruminants, porcines, horses, camelids, dogs, cats, or humans. Lingual lipase or pregastric esterase as a nutritional supplement may substantially improve the digestion of fats in mammals unable to effectively digest fats. The lingual lipase or esterase is preferably from an animal source. The composition may contain butterfat, micellar casein, whey, non-denatured proteins, and a source of lactose. Methods of treating fat maldigestion with the compositions are also disclosed.
Composition for preventing or improving impaired renal function, pharmaceutical composition, food/beverage composition, and method of preventing or improving impaired renal function using the composition for preventing or improving impaired renal function
Provided is a composition for preventing or improving impaired renal function, containing Bifidobacterium breve as an active ingredient. The composition for preventing or improving impaired renal function is capable of reducing blood creatinine levels. The composition for preventing or improving impaired renal function can also be used in a pharmaceutical composition or a food or beverage product composition.
Composition for preventing or improving impaired renal function, pharmaceutical composition, food/beverage composition, and method of preventing or improving impaired renal function using the composition for preventing or improving impaired renal function
Provided is a composition for preventing or improving impaired renal function, containing Bifidobacterium breve as an active ingredient. The composition for preventing or improving impaired renal function is capable of reducing blood creatinine levels. The composition for preventing or improving impaired renal function can also be used in a pharmaceutical composition or a food or beverage product composition.
Hydrated and anhydrous polymorphs of 2'-O-fucosyllactose and their production methods
This invention describes new hydrated and anhydrous polymorphs of 2′-O-fucosyllactose (2′FL): Polymorph A 2′FL-3/2H.sub.2O, Polymorph B 2TL-5/2 H.sub.2O and anhydrous Polymorph C. There is also a description of the methods for obtaining them, and of a new method for preparing Polymorph I already known in the literature.
Hydrated and anhydrous polymorphs of 2'-O-fucosyllactose and their production methods
This invention describes new hydrated and anhydrous polymorphs of 2′-O-fucosyllactose (2′FL): Polymorph A 2′FL-3/2H.sub.2O, Polymorph B 2TL-5/2 H.sub.2O and anhydrous Polymorph C. There is also a description of the methods for obtaining them, and of a new method for preparing Polymorph I already known in the literature.